Differing from GO203 that interferes MUC1-C dimerization, our research highlighted a new perspective of targeting N-terminal O-glycosylation could be promising to promote drug sensitivity and efficacy, no matter for early-stage cancer patients or the ones that have developed drug resistance. Here, MUC1 is linked to cancer.